PEG-MGF

Also known as: Pegylated MGF, PEGylated Mechano Growth Factor

Evidence Tier Dextreme riskadvancednot approved

PEGylated MGF with no identified human exposure data per FDA. Extreme platform risk.

FDA Safety Flag

The FDA has identified this substance as one that may present significant safety risks when used in compounding, including concerns about immunogenicity, impurity characterization, and/or insufficient safety information.

WADA S2

This substance falls under WADA S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics). If you are subject to anti-doping rules, this category of substances is prohibited at all times.

Extreme Risk

This substance is in the extreme platform risk category due to growth-factor signaling, mitogenic potential, or complete absence of human safety data. Exercise maximum caution.

No Human Data

No human exposure data has been identified for this substance. All available evidence comes from animal models or in vitro studies. Safety in humans is completely unknown.

Overview

PEG-MGF is a pegylated version of Mechano Growth Factor. FDA reports it has not identified any human exposure data for PEG-MGF drug products and flags immunogenicity/characterization complexity. If PEGylated, characterization of PEG conjugation distribution and impurity profile is required â€” not just 'purity %.' This is an extreme uncertainty and compliance risk item.

Research Details

Mechanism of Action

PEGylated MGF designed for prolonged activity; mechanism relates to IGF-1 splice variant muscle repair signaling.

Study Dose Range

No identified human exposure data per FDA.

Administration Routes

subcutaneous

Onset / Timeline

Unknown in humans.

Expected Effects

Proposed prolonged muscle repair signaling; claims largely unverified.

Adverse Effects

FDA flags immunogenicity/characterization complexity; no human exposure data identified.

Contraindications

No data; extreme uncertainty.

Interaction Notes

Unknown.

Related Goals

Muscle Growth & Strength

Known Interactions

contraindicated with IGF-1 LR3

High-risk IGF/MGF clustering; insufficient safety basis for consumer routing; FDA flags PEG-MGF compounding risks and no identified human exposure data.

contraindicated with Follistatin

Growth-factor cluster; insufficient safety basis for consumer routing.

caution with FOXO4-DRI

High uncertainty + growth-factor cluster.

Available From

No vendors currently listed for this peptide.

Frequently Compared

CJC-1295

Long-acting GHRH analogue studied in human trials for sustained GH/IGF-1 elevation.

Tier B

Ipamorelin

Selective GHSR agonist profiled for more targeted GH release with less ACTH/cortisol spillover than earlier secretagogues.

Tier B-C

GHRP-2

GH secretagogue studied in human stimulation tests with documented endocrine spillover effects.

Tier B

GHRP-6

GH secretagogue with phase I PK data in humans. FDA has flagged compounding safety concerns.

Tier B

Information provided for educational and research reference only. Not medical advice. Not for diagnosing, treating, curing, or preventing disease. Products referenced are labeled Research Use Only (RUO) by vendors; not for human or veterinary use.